Loading
TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.
E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators. Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.83, animal model 0.60, genetic association 0.00, somatic mutation 0.96). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Pleural Mesothelioma.
In plain words · TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.
TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.
E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators.
No product in this corpus aims at TRAF7 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 2001. Earliest sequence paper UniProt cites for the protein: Wiemann et al, Genome Res, 2001, "Towards a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs". Source.
Sources: HGNC HGNC:20456 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6Q0C0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000131653 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.52, skin cancer 0.54 (GraphQL API, CC0)); IntOGen TRAF7 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators. Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation. Plays a role in the phosphorylation of MAPK1 and/or MAPK3, probably via its interaction with MAP3K3. Negatively regulates RLR-mediated innate immunity by promoting 'Lys-48'-linked ubiquitination of TBK1 through its RING domain to inhibit the cellular antiviral response. Promotes 'Lys-29'-linked polyubiquitination of NEMO/IKBKG and RELA leading to targeting these two proteins to lysosomal degradative pathways, reducing the transcriptional activity of NF-kappa-B. Location: Cytoplasmic vesicle; Cytoplasm; Nucleus (UniProt). Locus 16p13.3 (HGNC).
Query for this target: (TITLE:"TRAF7" OR ABSTRACT:"TRAF7" OR TITLE:"TNF receptor associated factor 7" OR ABSTRACT:"TNF receptor associated factor 7" OR TITLE:"E3 ubiquitin-protein ligase TRAF7" OR ABSTRACT:"E3 ubiquitin-protein ligase TRAF7" OR TITLE:"RNF119" OR ABSTRACT:"RNF119" OR TITLE:"DKFZp586I021" OR ABSTRACT:"DKFZp586I021" OR TITLE:"MGC7807" OR ABSTRACT:"MGC7807") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TRAF7, not a curated reading list.
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen, Melanoma.
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
Shares Pleural mesothelioma, Mesothelioma, IntOGen.